Lorvotuzumab is an immunoconjugate consisting of cytotoxic maytansinoid drug DM1 and antibody against CD56. CD56 is highly expressed on almost all multiple myeloma cells. It is administered weekly for 3 weeks as an intravenous infusion every 28 days. In addition, Lenalidomide and Dexamethasone will be given in combination with Lorvotuzmab. This study will target patients with relapsed or refractory CD56-positive miltiple myeloma.
Type(s) of Cancer:
Epp Goodwin at (210) 450-5798